Black Diamond Therapeutics, Inc. (BDTX)
BDTXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$1.79
-0.0700 (-3.76%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.60 +0.31%
- Market cap
- $91.64m
- P/E
- –
- EPS, last 4 quarters
- $-0.6200
- Dividend yield
- –
- Day range
- $1.58 to $1.91
- 52-week range
- $1.60 to $4.94
- Average volume
- 699.7k
- Previous close
- $1.86
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $11.00, +514.5% from here
Earnings
next estimate $-0.0300Next report Nov 12, 2026
Sep 2025
+31.8%
Dec 2025
+22.2%
Mar 2026
+11.1%
Jun 2026
+5.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$10.98m | -$17.61m | -$11.26m | -$12.06m |
| Net income | -$8.50m | -$15.12m | -$9.04m | -$9.90m |
News
8 latest- Black Diamond Posts Strong Silevertinib Data; FDA Supports Phase 3 Path; Shares Rise RTTNews · 9 hours ago
- Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?Zacks · Sep 4, 2026
- Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA PathMarketBeat · Jun 6, 2026
- BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh CatalystZacks · May 27, 2026
- Black Diamond Stock Outlook After Q1 Beat and Cash RunwayZacks · May 27, 2026
- BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to KnowZacks · May 27, 2026
- BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study DataZacks · May 25, 2026
- Black Diamond Plunges Despite Positive Phase 2 Results For Silevertinib In 1L NSCLC RTTNews · May 22, 2026
The company
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- blackdiamondtherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.